Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibiotic combo shows promise against superbug infections

NCT ID NCT03510351

Disease control Sponsor: Temple University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at 200 adults with multidrug-resistant Pseudomonas infections who were treated with the antibiotic combination ceftolozane-tazobactam. Researchers tracked how many patients survived at 30 days and while in the hospital, and whether follow-up cultures showed the infection was cleared. The goal was to see if this drug works against these tough-to-treat bacteria.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ceftolozane-tazobactam
What this could lead to
If successful, this could confirm ceftolozane-tazobactam as a reliable treatment for hard-to-treat Pseudomonas infections, potentially saving lives.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. The bacteria may still develop resistance, and individual patient outcomes vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Feb 2017

Finished

Feb 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who had Pseudomonas aeruginosa infection and received ceftolozane-tazobactam for at least 24 hrs for treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Greater than 18 years old * Cultures positive Pseudomonas aeruginosa from any source * Received ceftolozane-tazobactam for at least 24 hrs Exclusion Criteria: * Protected populations * Prisoners, pregnant women, children

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pseudomonas aeruginosa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pseudomonas aeruginosa infectious disease Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pseudomonas aeruginosa Pseudomonas infections

Contacts and locations

Locations

  • Temple University, School of Pharmacy

    Philadelphia, Pennsylvania, 19140, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.